JIANG Jingzhu 1 , LI Haoquan 1 , WANG Zaiguo 1 , YE Zhenwei 1 , CHEN Yunhao 1 , ZHANG Weibiao 2 , LIAO Jingsheng 3
  • 1. Department of Hepatobiliary and Pancreatic Surgery, Dongguan Hospital Affiliated to Southern Medical University, Dongguan, Guangdong 523059, P. R. China;
  • 2. Nuclear Medicine Department, Dongguan Hospital Affiliated to Southern Medical University, Dongguan, Guangdong 523059, P. R. China;
  • 3. Internal Medicine of Digestive Oncology, Dongguan Hospital Affiliated to Southern Medical University, Dongguan, Guangdong 523059, P. R. China;
WANG Zaiguo, Email: wangzaiguo@sina.com
hepatocellular carcinoma; recurrent cancer; treatment; regorafenib; camrelizumab
10.7507/1007-9424.202207040
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective  To explore a new method for the treatment of refractory recurrent liver cancer. Methods  The treatment process and effect of a patient with refractory recurrent liver cancer who received complete remission (CR) treated with second-line targeted drug regorafenib combined with camrelizumab in the Department of Hepatobiliary and Pancreatic Surgery of Dongguan Hospital Affiliated to Southern Medical University were retrospectively analyzed and summarized. Results  In the previous 3 years, the patient underwent radical ablation, resection of recurrent cancer in the middle lobe of the liver, ablation of recurrent cancer in S2 and S8 segments of the liver, and multidisciplinary treatment with the first-line targeted drug lenvatinib, extensive intrahepatic recurrence and metastasis still occurred. Finally, the patient was treated with the second-line targeted drug regorafenib combined with camrelizumab for systemic treatment. All the intrahepatic lesions were liquefied and necrotic, and most of them were significantly reduced or disappeared, AFP decreased from the highest peak of 20 867.00 μg/L to normal. The therapeutic effect of CR was evaluated and remained stable for more than 12 months. There were no obvious toxic and side effects. The patient had a good quality of life and insisted on working normally. Conclusion  The second-line targeted drug regorafenib combined with new immunotherapy may still have curative effect on refractory recurrent liver cancer after various comprehensive treatment failures, and even obtain the hope and opportunity of long-term tumor-free survival.

Citation： JIANG Jingzhu, LI Haoquan, WANG Zaiguo, YE Zhenwei, CHEN Yunhao, ZHANG Weibiao, LIAO Jingsheng. Clinical experience of regorafenib combined with camrelizumab in the treatment of refractory recurrent liver cancer with complete remission. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(9): 1149-1153. doi: 10.7507/1007-9424.202207040 Copy